FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2012608933> ?p ?o ?g. }

• W2012608933 endingPage "e101286" @default.
• W2012608933 startingPage "e101286" @default.
• W2012608933 abstract "While response rates to BRAF inhibitiors (BRAFi) are high, disease progression emerges quickly. One strategy to delay the onset of resistance is to target anti-apoptotic proteins such as BCL-2, known to be associated with a poor prognosis. We analyzed BCL-2 family member expression levels of 34 samples from 17 patients collected before and 10 to 14 days after treatment initiation with either vemurafenib or dabrafenib/trametinib combination. The observed changes in mRNA and protein levels with BRAFi treatment led us to hypothesize that combining BRAFi with a BCL-2 inhibitor (the BH3-mimetic navitoclax) would improve outcome. We tested this hypothesis in cell lines and in mice. Pretreatment mRNA levels of BCL-2 negatively correlated with maximal tumor regression. Early increases in mRNA levels were seen in BIM, BCL-XL, BID and BCL2-W, as were decreases in MCL-1 and BCL2A. No significant changes were observed with BCL-2. Using reverse phase protein array (RPPA), significant increases in protein levels were found in BIM and BID. No changes in mRNA or protein correlated with response. Concurrent BRAF (PLX4720) and BCL2 (navitoclax) inhibition synergistically reduced viability in BRAF mutant cell lines and correlated with down-modulation of MCL-1 and BIM induction after PLX4720 treatment. In xenograft models, navitoclax enhanced the efficacy of PLX4720. The combination of a selective BRAF inhibitor with a BH3-mimetic promises to be an important therapeutic strategy capable of enhancing the clinical efficacy of BRAF inhibition in many patients that might otherwise succumb quickly to de novo resistance. Trial Registrations: ClinicalTrials.gov NCT01006980; ClinicalTrials.gov NCT01107418; ClinicalTrials.gov NCT01264380; ClinicalTrials.gov NCT01248936; ClinicalTrials.gov NCT00949702; ClinicalTrials.gov NCT01072175" @default.
• W2012608933 created "2016-06-24" @default.
• W2012608933 creator A5008479799 @default.
• W2012608933 creator A5023174631 @default.
• W2012608933 creator A5028008077 @default.
• W2012608933 creator A5035427219 @default.
• W2012608933 creator A5040776645 @default.
• W2012608933 creator A5042328102 @default.
• W2012608933 creator A5047185974 @default.
• W2012608933 creator A5048327749 @default.
• W2012608933 creator A5060478837 @default.
• W2012608933 creator A5061578231 @default.
• W2012608933 creator A5066250381 @default.
• W2012608933 creator A5071770314 @default.
• W2012608933 creator A5071928943 @default.
• W2012608933 creator A5073995758 @default.
• W2012608933 creator A5078874539 @default.
• W2012608933 creator A5091053901 @default.
• W2012608933 date "2014-07-01" @default.
• W2012608933 modified "2023-10-16" @default.
• W2012608933 title "Clinical Profiling of BCL-2 Family Members in the Setting of BRAF Inhibition Offers a Rationale for Targeting De Novo Resistance Using BH3 Mimetics" @default.
• W2012608933 cites W1560370693 @default.
• W2012608933 cites W1821265034 @default.
• W2012608933 cites W1971947883 @default.
• W2012608933 cites W1977258127 @default.
• W2012608933 cites W1979274840 @default.
• W2012608933 cites W1999025555 @default.
• W2012608933 cites W2013178885 @default.
• W2012608933 cites W2017187984 @default.
• W2012608933 cites W2018167187 @default.
• W2012608933 cites W2024085992 @default.
• W2012608933 cites W2026208222 @default.
• W2012608933 cites W2029712223 @default.
• W2012608933 cites W2032211985 @default.
• W2012608933 cites W2043058822 @default.
• W2012608933 cites W2053473615 @default.
• W2012608933 cites W2055624262 @default.
• W2012608933 cites W2079681905 @default.
• W2012608933 cites W2085419794 @default.
• W2012608933 cites W2096439168 @default.
• W2012608933 cites W2098587255 @default.
• W2012608933 cites W2099604307 @default.
• W2012608933 cites W2100614336 @default.
• W2012608933 cites W2104205745 @default.
• W2012608933 cites W2106494998 @default.
• W2012608933 cites W2112396699 @default.
• W2012608933 cites W2113947805 @default.
• W2012608933 cites W2119543578 @default.
• W2012608933 cites W2123437999 @default.
• W2012608933 cites W2128542677 @default.
• W2012608933 cites W2134490812 @default.
• W2012608933 cites W2136120524 @default.
• W2012608933 cites W2141674733 @default.
• W2012608933 cites W2145502912 @default.
• W2012608933 cites W2153056550 @default.
• W2012608933 cites W2155381255 @default.
• W2012608933 cites W2157144029 @default.
• W2012608933 cites W2161730699 @default.
• W2012608933 cites W2166262263 @default.
• W2012608933 cites W2167334545 @default.
• W2012608933 cites W2167690894 @default.
• W2012608933 cites W2168143310 @default.
• W2012608933 cites W2168632005 @default.
• W2012608933 cites W2171367970 @default.
• W2012608933 cites W2279761289 @default.
• W2012608933 doi "https://doi.org/10.1371/journal.pone.0101286" @default.
• W2012608933 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4077767" @default.
• W2012608933 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/24983357" @default.
• W2012608933 hasPublicationYear "2014" @default.
• W2012608933 type Work @default.
• W2012608933 sameAs 2012608933 @default.
• W2012608933 citedByCount "42" @default.
• W2012608933 countsByYear W20126089332014 @default.
• W2012608933 countsByYear W20126089332015 @default.
• W2012608933 countsByYear W20126089332016 @default.
• W2012608933 countsByYear W20126089332017 @default.
• W2012608933 countsByYear W20126089332018 @default.
• W2012608933 countsByYear W20126089332019 @default.
• W2012608933 countsByYear W20126089332020 @default.
• W2012608933 countsByYear W20126089332021 @default.
• W2012608933 countsByYear W20126089332022 @default.
• W2012608933 countsByYear W20126089332023 @default.
• W2012608933 crossrefType "journal-article" @default.
• W2012608933 hasAuthorship W2012608933A5008479799 @default.
• W2012608933 hasAuthorship W2012608933A5023174631 @default.
• W2012608933 hasAuthorship W2012608933A5028008077 @default.
• W2012608933 hasAuthorship W2012608933A5035427219 @default.
• W2012608933 hasAuthorship W2012608933A5040776645 @default.
• W2012608933 hasAuthorship W2012608933A5042328102 @default.
• W2012608933 hasAuthorship W2012608933A5047185974 @default.
• W2012608933 hasAuthorship W2012608933A5048327749 @default.
• W2012608933 hasAuthorship W2012608933A5060478837 @default.
• W2012608933 hasAuthorship W2012608933A5061578231 @default.
• W2012608933 hasAuthorship W2012608933A5066250381 @default.
• W2012608933 hasAuthorship W2012608933A5071770314 @default.
• W2012608933 hasAuthorship W2012608933A5071928943 @default.
• W2012608933 hasAuthorship W2012608933A5073995758 @default.
• W2012608933 hasAuthorship W2012608933A5078874539 @default.

• next